"For the accelerator's first program, Janssen is p
Post# of 30028
Posted On: 02/12/2015 9:15:17 PM
Re: biotechexpert #16702
"For the accelerator's first program, Janssen is partnering with the Juvenile Diabetes Research Foundation to find ways to prevent Type 1 diabetes, a complex, expensive immune disorder that can cause blindness, amputations and premature death. It involves the immune system steadily destroying beta cells in the pancreas that produce insulin, which is needed to help convert blood sugar into energy."
I found an interesting article from 2010:
It is about Pfizer and JDRF but there was a statement that stuck out
“Drugs that can stimulate the replication of insulin-producing cells and expand beta cell mass have the potential to reverse type 1 diabetes,” said Alan J. Lewis, Ph.D., President and Chief Executive Officer of JDRF. “This program may accelerate one of JDRF’s key research goals: to find ways to restore the body’s ability to make insulin.”
http://jdrf.org/press-releases/jdrf-announces...jerusalem/
I wonder what company has this potential !?
I found an interesting article from 2010:
It is about Pfizer and JDRF but there was a statement that stuck out
“Drugs that can stimulate the replication of insulin-producing cells and expand beta cell mass have the potential to reverse type 1 diabetes,” said Alan J. Lewis, Ph.D., President and Chief Executive Officer of JDRF. “This program may accelerate one of JDRF’s key research goals: to find ways to restore the body’s ability to make insulin.”
http://jdrf.org/press-releases/jdrf-announces...jerusalem/
I wonder what company has this potential !?
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼